| PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85? | None |
| mutant forms of p85alpha may play an oncogenic role in bladder cancer | bladder, |
| products of the Pik3r1 gene contribute to transformation efficiency by BCR-ABL and there is a role for PI3K signaling in B-lineage transformation by ABL oncogenes. | None |
| study reports a 3.0 angstrom resolution structure of a complex between p110alpha and a polypeptide containing the p110alpha-binding domains of p85alpha; results suggest specific mechanisms for the effect of oncogenic mutations in p110alpha and p85alpha | None |
| structure of the complex between the catalytic subunit of PI3Kalpha, p110alpha, & a portion of its regulatory subunit, p85alpha reveals the majority of the oncogenic mutations occur at the interfaces between p110 domains & between p110 & p85 domains | None |
| Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. | None |
| The role of infectious bursal disease virus proteins in the activation of the P85alpha subunit of phosphatidylinositol 3-kinase and akt proto-oncogene are reported. | None |
| genetic association studies in populations in Ireland and Belgium: Data suggest that frequencies of mutations in PIK3R1, MET (MET proto-oncogene receptor tyrosine kinase), and BRAF (B-Raf proto-oncogene) vary by demographic location. | None |